Candel Therapeutics (CADL) Enterprise Value (2020 - 2025)
Candel Therapeutics (CADL) reported Enterprise Value of -$119.7 million for Q4 2025, down 16.64% on a YoY basis from -$143.6 million in Q4 2024, and down 37.68% sequentially from -$87.0 million in Q3 2025.
Candel Therapeutics (CADL) Enterprise Value (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Enterprise Value data on file, last reported at -$119.7 million in Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 16.64% year-over-year to -$119.7 million; the trailing twelve-month figure through Dec 2025 stood at -$119.7 million (down 16.64% YoY), and the FY2025 full-year result was -$119.7 million, down 16.64% from the prior year.
- Enterprise Value retreated to -$119.7 million in Q4 2025, from -$87.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$16.6 million in Q3 2024 to a low of -$119.7 million in Q4 2025.
- A 5-year average of -$67.3 million and a median of -$77.2 million in 2022 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value jumped 61.49% in 2024 and plunged 425.2% in 2025, its largest moves.
- Tracing CADL's Enterprise Value over 5 years: stood at -$82.6 million in 2021, then gained by 15.23% to -$70.1 million in 2022, then soared by 49.45% to -$35.4 million in 2023, then sank by 189.88% to -$102.7 million in 2024, then decreased by 16.64% to -$119.7 million in 2025.
- Business Quant data shows CADL's Enterprise Value at -$119.7 million in Q4 2025, -$87.0 million in Q3 2025, and -$100.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | -119.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -119.73 Mn |
| Sep 30, 2025 | -86.96 Mn |
| Jun 30, 2025 | -100.69 Mn |
| Mar 31, 2025 | -92.17 Mn |
| Dec 31, 2024 | -102.65 Mn |
| Sep 30, 2024 | -16.56 Mn |
| Jun 30, 2024 | -21.45 Mn |
| Mar 31, 2024 | -25.71 Mn |
| Dec 31, 2023 | -35.41 Mn |
| Sep 30, 2023 | -43.00 Mn |
| Jun 30, 2023 | -51.90 Mn |
| Mar 31, 2023 | -59.26 Mn |
| Dec 31, 2022 | -70.06 Mn |
| Sep 30, 2022 | -77.18 Mn |
| Jun 30, 2022 | -86.78 Mn |
| Mar 31, 2022 | -94.32 Mn |
| Dec 31, 2021 | -82.64 Mn |
| Sep 30, 2021 | -88.39 Mn |
| Jun 30, 2021 | -24.32 Mn |
| Dec 31, 2020 | -35.05 Mn |